Siemens Corporate Research (SCR), Inc. announced that it developed the RAPID2 system to speed the biomarker discovery process for the development of rapid diagnostic tests. This system marries the power of information technology with today"s improved genomic sequencing to quickly identify genomic signatures unique to the set of organisms to be detected. These signatures are the foundation for a new generation of molecular diagnostic tests for the rapid detection of healthcare-associated infections such as the potentially deadly Methicillin-Resistant Staphylococcus Aureus (MRSA).